PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsNesiritide
Nesiritide
Natrecor (nesiritide) is a protein pharmaceutical. Nesiritide was first approved as Natrecor on 2001-08-10. It is used to treat paroxysmal dyspnea in the USA. It is known to target atrial natriuretic peptide receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nesiritide
Tradename
Company
Number
Date
Products
NATRECORSciosN-020920 DISCN2001-08-10
1 products, RLD
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
paroxysmal dyspnea—D004418I50.1
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C01: Cardiac therapy drugs
— C01D: Vasodilators used in cardiac diseases
— C01DX: Other vasodilators used in cardiac diseases in atc
— C01DX19: Nesiritide
HCPCS
Code
Description
J2325
Injection, nesiritide, 0.1 mg
Clinical
Clinical Trials
263 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333HP_0001635I50819132051105
HypertensionD006973EFO_0000537I1042—9821
CardiomyopathiesD009202EFO_0000318I421243917
Cardiovascular diseasesD002318HP_0001626—1—111013
Heart diseasesD006331EFO_0003777I51.9—221812
Renal insufficiencyD051437HP_0000083N193511412
DyspneaD004417HP_0002094R06.0—112610
Myocardial ischemiaD017202EFO_1001375I20-I25—21148
Pulmonary hypertensionD006976EFO_0001361I27.20———538
ObesityD009765EFO_0001073E66.92——147
Show 27 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.0——1—78
Kidney diseasesD007674EFO_0003086N08——1—56
Acute kidney injuryD058186HP_0001919N17111—35
Acute coronary syndromeD054058EFO_0005672——11—24
Cardiopulmonary bypassD002315——121—14
Lung neoplasmsD008175HP_0100526C34.90——1—23
Coronary artery bypassD001026EFO_0003776——11—13
Obstructive lung diseasesD008173HP_0006536——11—13
DeathD003643PATO_0001422———1—12
Heart disease risk factorsD000082742————1——1
Show 6 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myocardial infarctionD009203EFO_0000612I2111——79
Congenital heart defectsD006330HP_0001627Q24.912——57
InfarctionD007238EFO_0009463—11——46
IschemiaD007511EFO_0000556——1——34
SyndromeD013577——12——24
Chronic obstructive pulmonary diseaseD029424EFO_0000341J44.9—1——23
Congenital abnormalitiesD000013EFO_0003915Q89.912——13
Chronic kidney failureD007676EFO_0003884N18.9—1——12
Systolic heart failureD054143EFO_1001207I50.20—1——12
Systolic murmursD054160—R01.112———2
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insulin resistanceD007333HP_0000855—1————1
HyperinsulinismD006946HP_0000842E16.11————1
Cardiac resynchronization therapyD058406——1————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
SepsisD018805HP_0100806A41.9————77
StrokeD020521EFO_0000712I63.9————66
Breast neoplasmsD001943EFO_0003869C50————66
Aortic valve stenosisD001024HP_0001650—————66
Pathologic constrictionD003251——————66
Chronic renal insufficiencyD051436—N18————66
ToxemiaD014115——————66
CardiotoxicityD066126EFO_1001482—————55
Covid-19D000086382——————55
Type 2 diabetes mellitusD003924EFO_0001360E11————44
Show 113 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNesiritide
INNnesiritide
Description
Natriuretic peptides B [Precursor]
Classification
Protein
Drug classpeptides: atrial natriuretic type substances
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI—
ChEMBL IDCHEMBL1201668
ChEBI ID—
PubChem CID16134381
DrugBankDB04899
UNII IDP7WI8UL647 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NPR1
NPR1
Organism
Homo sapiens
Gene name
NPR1
Gene synonyms
ANPRA
NCBI Gene ID
Protein name
atrial natriuretic peptide receptor 1
Protein synonyms
ANP-A, ANPR-A, Atrial natriuretic peptide receptor type A, atrionatriuretic peptide receptor A, GC-A, Guanylate cyclase A, natriuretic peptide A type receptor, natriuretic peptide receptor A, natriuretic peptide receptor A/guanylate cyclase A (atrionatriuretic peptide receptor A), NPR-A, testicular tissue protein Li 20
Uniprot ID
Mouse ortholog
Npr1 (18160)
atrial natriuretic peptide receptor 1 (P18293)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,369 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
359 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use